0DRP Stock Chart & Stats
€3.06
€0.00(0.00%)
At close: 4:00 PM EST
€3.06
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.20 - €3.77
Previous CloseN/A
Volume0.00
Average Volume (3M)1.76K
Market Cap
€42.73M
Enterprise Value€38.10M
Total Cash (Recent Filing)€6.70M
Total Debt (Recent Filing)€600.00K
Price to Earnings (P/E)15.7
Beta1.21
Next Earnings
Aug 05, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding12,230,093
10 Day Avg. Volume2,346
30 Day Avg. Volume1,756
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
0DRP FAQ
What was Biohit Oyj’s price range in the past 12 months?
Biohit Oyj lowest share price was €2.20 and its highest was €3.77 in the past 12 months.
What is Biohit Oyj’s market cap?
Biohit Oyj’s market cap is €42.73M.
When is Biohit Oyj’s upcoming earnings report date?
Biohit Oyj’s upcoming earnings report date is Aug 05, 2026 which is tomorrow.
How were Biohit Oyj’s earnings last quarter?
Biohit Oyj released its earnings results on Feb 11, 2026. The company reported €0.118 earnings per share for the quarter, beating the consensus estimate of €0.114 by €0.004.
Is Biohit Oyj overvalued?
According to Wall Street analysts Biohit Oyj’s price is currently Overvalued.
Does Biohit Oyj pay dividends?
Biohit Oyj does not currently pay dividends.
What is Biohit Oyj’s EPS estimate?
Biohit Oyj’s EPS estimate is 0.06.
How many shares outstanding does Biohit Oyj have?
Biohit Oyj has 12,230,093 shares outstanding.
What happened to Biohit Oyj’s price movement after its last earnings report?
Biohit Oyj reported an EPS of €0.118 in its last earnings report, beating expectations of €0.114. Following the earnings report the stock price went down -7.715%.
Which hedge fund is a major shareholder of Biohit Oyj?
Currently, no hedge funds are holding shares in GB:0DRP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biohit Oyj
Helsinki-based Biohit Oyj is a biotechnology company that specializes in developing and distributing diagnostic tests and analytical systems worldwide for healthcare providers and research institutions. Their comprehensive portfolio of diagnostic solutions includes the GastroPanel test, designed for evaluating stomach conditions and associated risks, alongside tests for active vitamin B12 levels (Biohit Active B12) and vitamin D status (Biohit Total). They also offer the Biohit Calprotectin test, various methods for detecting Helicobacter pylori infection from biopsy samples, the ColonView Quick Test for identifying fecal occult blood, rapid tests for Lactose Intolerance and Celiac Disease, and the GA-map Dysbiosis test for detailed gut microbiota DNA analysis. Beyond diagnostics, Biohit manufactures products that bind carcinogenic acetaldehyde into harmless compounds, such as Acetium capsules for individuals with low stomach acidity, and Acetium lozenges, which neutralize acetaldehyde in smokers' saliva. The company also supplies monoclonal antibodies crucial for research in cellular pathology, neurobiology, oncology, and human gastric biomarkers. Additionally, their offerings extend to laboratory instrumentation, including microplate readers, strip washers, quick test readers, and the ThunderBolt automated immunoassay analyzer, complemented by comprehensive service laboratory provisions. Biohit Oyj was founded in 1988.